Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer

被引:0
作者
Molly A. Nelson
Worapol Ngamcherdtrakul
Shiuh-Wen Luoh
Wassana Yantasee
机构
[1] PDX Pharmaceuticals,Department of Biomedical Engineering
[2] Inc.,undefined
[3] VA Portland Health Care System,undefined
[4] Knight Cancer Institute,undefined
[5] Oregon Health and Science University,undefined
[6] Oregon Health and Science University,undefined
来源
Cancer and Metastasis Reviews | 2021年 / 40卷
关键词
Breast cancer; Immunotherapy; Tumor microenvironment; TILs; T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to either a pro-tumor or antitumor effect. Tumor-infiltrating CD8+ T cells and natural killer (NK) cells perform as effector cells against tumor cells and are associated with better clinical outcome. Immunotherapy approaches that improve the antitumor activity and proliferation of CD8+ T and NK cells include PD-1/PD-L1 blockade, CAR T cell therapy, or ex vivo-stimulated NK cells. A subset of CD8+ T cells, tissue-resident memory T cells, has also recently been associated with good prognosis in breast cancer patients, and has potential to serve as a predictive biomarker and therapeutic target. Tumor-infiltrating B cells also secrete apoptosis-inducing IgG antibodies and can act as antigen-presenting cells to prime CD4+ and CD8+ T cells. On the other hand, regulatory T and regulatory B cells modulate the immune response from CD8+ T cells and NK cells by secreting immunosuppressive cytokines and inhibiting maturation of antigen-presenting cells (APCs). These regulatory cells are typically associated with poor prognosis, therefore rendering suppression of their regulatory function a key immunotherapeutic strategy.
引用
收藏
页码:519 / 536
页数:17
相关论文
共 1035 条
[1]  
The L(2018)GLOBOCAN 2018: Counting the toll of cancer Lancet (London, England) 392 985-202
[2]  
Asano Y(2020)Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor-infiltrating lymphocytes Molecular and clinical oncology 13 195-113
[3]  
Kashiwagi S(2010)Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 28 105-62
[4]  
Goto W(2017)Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: A retrospective analysis of the CLEOPATRA study The Lancet. Oncology 18 52-82
[5]  
Takada K(2019)Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study JAMA Oncology 5 74-320
[6]  
Takahashi K(2018)Relationship between tumor infiltrating lymphocytes and progression in breast cancer Maedica 13 317-1466
[7]  
Shibutani M(1992)Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer Anticancer Res 12 1463-189
[8]  
Denkert C(2019)Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer Breast Cancer 26 180-632
[9]  
Loibl S(2013)FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis Molecular and clinical oncology 1 625-252
[10]  
Noske A(1998)Dendritic cells and the control of immunity Nature 392 245-266